Combination drug therapy
US6849599B2 · kind B2 · utility
4Cited by
11References
7Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 8, 2001 |
| Grant date | Feb 1, 2005 |
| Priority date | — |
| Expiry date | Mar 8, 2021 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K45/06
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides antineoplastic composition containing an inhibitor of angiogenesis and an inhibitor of DNA topoisomerase type I enzyme activity.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.